We use cookies for a better user experience. Read our Privacy Policy

I Agree

Pulmonary Drug Delivery Devices Market Forecast, 2022-2031

Pulmonary Drug Delivery Devices Market (Product Type: Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs), and Nebulizers) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Pulmonary Drug Delivery Devices Market Outlook 2031

  • The global pulmonary drug delivery devices market was valued at US$ 35.2 Bn in 2021
  • It is estimated to grow at a CAGR of 4.7% from 2022 to 2031
  • The global market is expected to exceed the value of US$ 49.5 Bn by the end of 2031

Analysts’ Viewpoint on Global Market Scenario

eHealth apps and telehealth are giving rise to remote patient monitoring in themarket. Although particle engineering holds potentials to improve clinical numbers, med-tech companies should take into consideration biological barriers for pulmonary drug delivery, nature of pulmonary infectious diseases, and deposition of inhaled particles. These considerations are helping manufacturers to develop robust pulmonary drug delivery devices. In addition, continuous advances in material sciences, microcarriers, disease etiology, and drug targeting strategies are becoming crucial for companies in the market for pulmonary drug delivery devices to gain a competitive edge over other market players.

Overview

Pulmonary drug delivery systems refer to technologies that are used to treat diseases such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis using pulmonary route of drug administration. These systems have been in medical use for more than six decades. However, recent technological advancements in pulmonary drug delivery systems have expanded their potential application in other diseases such as diabetes, lung cancer, and others.

The pulmonary drug delivery market deals with devices that help with the inhalation of drug formulation through mouth and further deposition of inhaled pharmacological agent in lower airways. The rise in prevalence of major respiratory problems such as COPD, asthma, and cystic fibrosis is a major factor driving the global market.

The global market has been segmented on the basis of product type, application, and distribution channel. In terms of product type, the global market has been classified into dry powder inhalers, metered dose inhalers, and nebulizers. Based on application, the global market has been categorized into asthma, COPD, cystic fibrosis, and others.

In terms of distribution channel, the global market has been divided into retail pharmacies, hospital pharmacies, and e-commerce.

Request a sample to get extensive insights into the Pulmonary Drug Delivery Devices Market

Increase in Prevalence and Incidence of Respiratory Diseases to Drive Global Market

The surge in trend of pulmonary drug delivery due to large absorptive area, thin absorptive mucosal membrane, and efficient blood supply is likely to propel the global market. The growing need of minimal invasive and effective treatment, and rise in the number of people with habit of smoking are projected to fuel the growth of the global market.

Moreover, increase in incidence of chronic respiratory diseases is projected to drive the demand for pulmonary drug delivery systems (PDDS) in the near future. According to data published by the Global Asthma Network (GAN) in “The Global Asthma Report 2014”, asthma affects around 334 million people globally. Rise in prevalence and incidence of respiratory diseases has led to an increase in the patient population, which in turn has fueled the demand for these systems. This consequent increase in demand is likely to propel the global market in the next few years.

Surge in Number of Initiatives Undertaken by Government and Non-Government Organizations

Rise in the number of initiatives undertaken by government and non-government organizations drives the global market, in terms of revenue. For instance, the CDC’s National Asthma Control Program (NACP) provides funds for educating asthma affected patients. Such initiatives are likely to increase awareness about asthma, which will drive the adoption of PDDS in the treatment of chronic obstructive pulmonary disease (COPD) and asthma.

Request a custom report on Pulmonary Drug Delivery Devices Market

High Adoption Rate of Metered Dose Inhalers for Effective Inhalation Therapy for Asthma

In terms of product type, the global pulmonary drug delivery devices market has been classified into dry powder inhalers, metered dose inhalers, and nebulizers. The metered dose inhalers (MDI) segment held key market share in 2020. Presence of major players involved in the development of novel MDIs and high acceptance rate of these devices in developing regions, such as Asia Pacific and Latin America, are the major factors propelling the segment.

Based on application, the global market has been categorized into asthma, COPD, cystic fibrosis, and others. The asthma segment held key share of the global market in 2020. An effective inhalation therapy that uses DPIs and MDIs is considered the basis of asthma management. The demand and usage of devices such as MDIs and DPIs for asthma management are increasing due to high number of people affected by asthma, which in turn fuels the growth of the asthma segment.

Rise in Hospitalizations to Fuel Growth of Global Pulmonary Drug Delivery Devices Market

Based on distribution channels, the global market has been categorized into retail pharmacies, hospital pharmacies, and e-commerce. The hospital pharmacies segment held notable share of the global market in 2021, and the trend is projected to continue in the near future. Hospitals offer extensive treatments, care, quick reimbursements, and insurance policies due to which patients prefer hospital pharmacies. Moreover, increase in the number of hospitalizations is anticipated to fuel the growth of the segment.

Regional Outlook

In terms of region, the global pulmonary drug delivery devices market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market in 2021, followed by Europe. This can be attributed to the increase in incidence of diseases such as COPD and asthma. Rise in the number of patients affected by these diseases increases the demand for diagnostic devices, including PDDS, thereby propelling the market in the region.

Analysis of Key Players

This report by Transparency Market Research profiles key players in the global market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. The global market is highly fragmented, with the presence of a number of international as well as regional players.

Leading players operating in the global market are Boehringer Ingelheim GmbH, Novartis AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., AstraZeneca plc, Merck & Co., Inc., MannKind Corporation, F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Mylan N.V., Omron Corporation, 3M Healthcare, Sunovion Pharmaceuticals, Inc., Koninklijke Philips N.V., Gerresheimer AG, Bespak, AptarGroup, Inc., SHL Group, Nypro Healthcare, Inc. (Jabil Circuit, Inc.), Hovione, and Chiesi Farmaceutici S.p.A., among others.

Key Developments in Global Pulmonary Drug Delivery Devices Market

The market is quite competitive, with key players engaged in mergers & acquisitions, new product development, collaborations & partnerships, and growth strategies to increase market penetration. Rise in the number of companies is expected to fuel competition in the near future. Hence, competitive rivalry in the respiratory market is expected to be high during the forecast period. Additionally, these players offer services that are aimed at enhancing the quality of drug delivery systems and better patient care. Moreover, the need of more efficient systems and competition among new entrants are anticipated to augment the global market in the next few years. Strategies adopted by players operating in the global pulmonary drug delivery devices market include:

  • In May 2017, Koninklijke Philips N.V. entered into a definitive agreement to acquire Respiratory Technologies, Inc. (RespirTech) in order to expand its respiratory care product portfolio

Global Pulmonary Drug Delivery Devices Market Snapshot

Attribute

Detail

Market Size Value in 2021

US$ 35.2 Bn

Market Forecast Value in 2031

US$ 49.5 Bn

Growth Rate (CAGR)

4.7%

Forecast Period

2022–2031

Historical Data Available for

2017–2020

Quantitative Units

US$ Bn for Value

Market Analysis

It includes cross segment analysis at global as well as regional level. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview.

Competition Landscape

  • Market Player - Competition Matrix (by tier and size of companies)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Product Type
    • Metered Dose Inhalers (MDIs)
    • Dry Powder Inhalers (DPIs)
    • Nebulizers
  • Application
    • Asthma
    • Chronic Obstructive Pulmonary Disease (COPD)
    • Cystic Fibrosis
    • Others
  • Distribution Channel
    • Retail Pharmacies
    • Hospital Pharmacies
    • E-commerce

Regions Covered

  • North America
  • Latin America
  • Europe
  • Latin America
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

 

  • Boehringer Ingelheim GmbH
  • Novartis AG
  • GlaxoSmithKline plc
  • Teva Pharmaceutical Industries Ltd.
  • AstraZeneca plc
  • Merck & Co., Inc.
  • MannKind Corporation
  • F. Hoffmann-La Roche Ltd.
  • Bristol-Myers Squibb Company
  • Mylan N.V.
  • Omron Corporation
  • 3M Healthcare
  • Sunovion Pharmaceuticals, Inc.
  • Koninklijke Philips N.V.
  • Gerresheimer AG
  • Bespak
  • AptarGroup, Inc.
  • SHL Group
  • Nypro Healthcare Inc. (Jabil Circuit Inc.)
  • Hovione
  • Chiesi Farmaceutici S.p.A. Other prominent players

Customization Scope

Available upon request

Pricing

Available upon request

Pulmonary Drug Delivery Devices Market Forecast, 2022-2031

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

How big was the global pulmonary drug delivery devices market in 2021?

The global market was valued at US$ 35.2 Bn in 2021.

How big will the pulmonary drug delivery devices market in 2031?

The global market is likely to surpass US$ 49.5 Bn by 2031.

What is the CAGR of global pulmonary drug delivery devices market during the forecast period (2022-2031)?

The global market is anticipated to record a CAGR of 4.7% from 2022 to 2031.

What are the prominent trends impacting the market growth?

Increase in the number of initiatives undertaken by government and non-government organizations, and rise in trend of pulmonary drug delivery devices positively impact the global market.

Which region held key market share during the forecast period?

North America is expected to be a potential revenue generator for vendors during the forecast period.

Who are the prominent players in global pulmonary drug delivery devices market?

Boehringer Ingelheim, GmbH Novartis AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., AstraZeneca plc Merck & Co., Inc. MannKind Corporation, F. Hoffmann-La Roche Ltd, Bristol-Myers, Squibb Company , Mylan N.V. Omron Corporation, 3M Healthcare, Sunovion Pharmaceuticals, Inc. Koninklijke Philips N.V. , Gerresheimer AG, Bespak AptarGroup, Inc. SHL Group Nypro Healthcare Inc. (Jabil Circuit Inc.) , Hovione

1. Preface

    1.1. Report Scope

    1.2. Market Segmentation

    1.3. Research Highlights

2. Assumptions and Research Methodology

    2.1. Assumptions

    2.2. Research Methodology

3. Executive Summary

4. Market Overview

    4.1. Product Type Overview

    4.2. Key Industry Events

    4.3. Market Opportunity Map

5. Market Dynamics

    5.1. Drivers and Restraints Snapshot Analysis

    5.2. Drivers

    5.3. Restraints

    5.4. Opportunity Analysis

    5.5. Opportunities

    5.6. Trends

    5.7. Porter’s Five Forces Analysis

    5.8. Value Chain Snapshot

6. Global Pulmonary Drugs Market Analysis, by Product Type

    6.1. Key Findings

    6.2. Introduction

    6.3. Global Pulmonary Drug Delivery Devices Market Value Share Analysis, by Product Type

    6.4. Global Pulmonary Drug Delivery Devices Market Forecast, by Product Type

        6.4.1. Global Dry Powder Inhalers (DPIs) Market Revenue (US$ Mn) and Volume (Million Units), 2017–2031

        6.4.2. Global Metered Dose Inhalers (MDIs) Market Revenue (US$ Mn) and Volume (Million Units), 2017–2031

        6.4.3. Global Nebulizers Market Revenue (US$ Mn) and Volume (Million Units), 2017–2031

    6.5. Global Pulmonary Drugs Market Attractiveness Analysis, by Product Type

    6.6. Key Trends

7. Global Pulmonary Drug Delivery Devices Market Analysis, by Application

    7.1. Key Findings

    7.2. Introduction

    7.3. Global Pulmonary Drug Delivery Devices Market Value Share Analysis, by Application, 2017 and 2031

    7.4. Global Pulmonary Drug Delivery Devices Market Size (US$ Mn) and volume (Million Units) Forecast, by Application, 2017–2031

        7.4.1. Global Asthma Market Revenue (US$ Mn) and volume (Million Units), 2017–2031

        7.4.2. Global COPD Market Revenue (US$ Mn) and volume (Million Units), 2017–2031

        7.4.3. Global Cystic Fibrosis Market Revenue (US$ Mn) and volume (Million Units), 2017–2031

        7.4.4. Global Other Applications Market Revenue (US$ Mn) and volume (Million Units), 2017–2031

        7.4.5. Global Pulmonary Drug Delivery Devices Market Attractiveness Analysis, by Application

    7.5. Key Trends

8. Pulmonary Drug Delivery Devices Market Analysis, by Distribution Channel

    8.1. Key Findings

    8.2. Introduction

    8.3. Global Pulmonary Drug Delivery Devices Market Value Share Analysis, by Distribution Channel, 2017 and 2031

    8.4. Global Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Distribution Channel, 2017–2031

        8.4.1. Global Retail Pharmacies Market Revenue (US$ Mn) and Volume (Million Units), 2017–2031

        8.4.2. Global Hospital Pharmacies Market Revenue (US$ Mn) and Volume (Million Units), 2017–2031

        8.4.3. Global E-commerce Market Revenue (US$ Mn) and Volume (Million Units), 2017–2031

    8.5. Global Pulmonary Drug Delivery Devices Market Attractiveness Analysis, by Distribution Channel

9. Pulmonary Drug Delivery Devices Market Analysis, by Region

    9.1. Global Scenario

    9.2. Global Pulmonary Drug Delivery Devices Market Value Share Analysis By Region, 2017 and 2031

    9.3. Global Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Region, 2017–2031

    9.4. Global Pulmonary Drug Delivery Devices Market Attractiveness Analysis, by Region

10. North America Pulmonary Drug Delivery Devices Market Analysis

    10.1. Key Findings

    10.2. North America Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, 2017–2031

    10.3. North America Pulmonary Drug Delivery Devices Market Size and Volume Y-o-Y Growth Projections, 2017–2031

    10.4. North America Market Attractiveness Analysis, by Country, 2022–2031

    10.5. North America Market Value Share Analysis, by Product Type, 2017 and 2031

    10.6. North America Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Product Type, 2017–2031

    10.7. North America Market Value Share Analysis, by Application, 2017 and 2031

    10.8. North America Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Application, 2017–2031

    10.9. North America Market Revenue Share Analysis, by Distribution Channel, 2017 and 2031

    10.10. North America Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Distribution Channel, 2017–2031

    10.11. North America Market Value Share Analysis, by Country, 2017 and 2031

    10.12. North America Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Country, 2017–2031

    10.13. North America Market Attractiveness Analysis, by Product Type, 2022–2031

    10.14. North America Market Attractiveness Analysis, by Application, 2022–2031

    10.15. North America Market Attractiveness Analysis, by Distribution Channel, 2022–2031

11. Europe Pulmonary Drug Delivery Devices Market Analysis

    11.1. Key Findings

    11.2. Europe Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, 2017–2031

    11.3. Europe Pulmonary Drug Delivery Devices Market Size and Volume Y-o-Y Growth Projections, 2017–2031

    11.4. Europe Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    11.5. Europe Market Value Share Analysis, by Product Type, 2017 and 2031

    11.6. Europe Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Product Type, 2017–2031

    11.7. Europe Market Value Share Analysis, by Application, 2017 and 2031

    11.8. Europe Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Application, 2017–2031

    11.9. Europe Market Revenue Share Analysis, by Distribution Channel, 2017 and 2031

    11.10. Europe Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Distribution Channel, 2017–2031

    11.11. Europe Market Value Share Analysis, by Country/Sub-region, 2017 and 2031

    11.12. Europe Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Country, 2017–2031

    11.13. Europe Market Attractiveness Analysis, by Product Type, 2022–2031

    11.14. Europe Market Attractiveness Analysis, by Application, 2022–2031

    11.15. Europe Market Attractiveness Analysis, by Distribution Channel, 2022–2031

12. Asia Pacific Pulmonary Drug Delivery Devices Market Analysis

    12.1. Key Findings

    12.2. Asia Pacific Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, 2017–2031

    12.3. Asia Pacific Pulmonary Drug Delivery Devices Market Size and Volume Y-o-Y Growth Projections, 2017–2031

    12.4. Asia Pacific Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    12.5. Asia Pacific Market Value Share Analysis, by Product Type, 2017 and 2031

    12.6. Asia Pacific Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Product Type, 2017–2031

    12.7. Asia Pacific Market Value Share Analysis, by Application, 2017 and 2031

    12.8. Asia Pacific Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Application, 2017–2031

    12.9. Asia Pacific Market Revenue Share Analysis, by Distribution Channel, 2017 and 2031

    12.10. Asia Pacific Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Distribution Channel, 2017–2031

    12.11. Asia Pacific Market Value Share Analysis, by Country/Sub-region, 2017 and 2031

    12.12. Asia Pacific Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Country, 2017–2031

    12.13. Asia Pacific Market Attractiveness Analysis, by Product Type, 2022–2031

    12.14. Asia Pacific Market Attractiveness Analysis, by Application, 2022–2031

    12.15. Asia Pacific Market Attractiveness Analysis, by Distribution Channel, 2022–2031

13. Latin America Pulmonary Drug Delivery Devices Market Analysis

    13.1. Key Findings

    13.2. Latin America Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, 2017–2031

    13.3. Latin America Pulmonary Drug Delivery Devices Market Size and Volume Y-o-Y Growth Projections, 2017–2031

    13.4. Latin America Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    13.5. Latin America Market Value Share Analysis, by Product Type, 2017 and 2031

    13.6. Latin America Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Product Type, 2017–2031

    13.7. Latin America Market Value Share Analysis, by Application, 2017 and 2031

    13.8. Latin America Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Application, 2017–2031

    13.9. Latin America Market Revenue Share Analysis, by Distribution Channel, 2017 and 2031

    13.10. Latin America Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Distribution Channel, 2017–2031

    13.11. Latin America Market Value Share Analysis, by Country/Sub-region, 2017 and 2031

    13.12. Latin America Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Country, 2017–2031

    13.13. Latin America Market Attractiveness Analysis, by Product Type, 2022–2031

    13.14. Latin America Market Attractiveness Analysis, by Application, 2022–2031

    13.15. Latin America Market Attractiveness Analysis, by Distribution Channel, 2022–2031

14. Middle East & Africa Pulmonary Drug Delivery Devices Market Analysis

    14.1. Key Findings

    14.2. Middle East & Africa Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, 2017–2031

    14.3. Middle East & Africa Pulmonary Drug Delivery Devices Market Size and Volume Y-o-Y Growth Projections, 2017–2031

    14.4. Middle East & Africa Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    14.5. Middle East & Africa Market Value Share Analysis, by Product Type, 2017 and 2031

    14.6. Middle East & Africa Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Product Type, 2017–2031

    14.7. Middle East & Africa Market Value Share Analysis, by Application, 2017 and 2031

    14.8. Middle East & Africa Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Application, 2017–2031

    14.9. Middle East & Africa Market Revenue Share Analysis, by Distribution Channel, 2017 and 2031

    14.10. Middle East & Africa Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Distribution Channel, 2017–2031

    14.11. Middle East & Africa Market Value Share Analysis, by Country/Sub-region, 2017 and 2031

    14.12. Middle East & Africa Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Country/Sub-region, 2017–2031

    14.13. Middle East & Africa Market Attractiveness Analysis, by Product Type, 2022–2031

    14.14. Middle East & Africa Market Attractiveness Analysis, by Application, 2022–2031

    14.15. Middle East & Africa Market Attractiveness Analysis, by Distribution Channel, 2022–2031

15. Competition Landscape

    15.1. Global Pulmonary Drugs Market Share Analysis, by Company, 2015

    15.2. Competitive Dashboard

    15.3. Pipeline Snapshot

16. Company Profiles

    16.1. Boehringer Ingelheim GmbH

        16.1.1. Company Overview

        16.1.2. Business Overview

        16.1.3. Financial Overview

        16.1.4. SWOT Analysis

        16.1.5. Strategic Overview

    16.2. Novartis AG

        16.2.1. Company Overview

        16.2.2. Business Overview

        16.2.3. Financial Overview

        16.2.4. SWOT Analysis

        16.2.5. Strategic Overview

    16.3. GlaxoSmithKline plc

        16.3.1. Company Overview

        16.3.2. Business Overview

        16.3.3. Financial Overview

        16.3.4. SWOT Analysis

        16.3.5. Strategic Overview

    16.4. AstraZeneca plc

        16.4.1. Company Overview

        16.4.2. Business Overview

        16.4.3. Financial Overview

        16.4.4. SWOT Analysis

        16.4.5. Strategic Overview

    16.5. Teva Pharmaceutical Industries Ltd.

        16.5.1. Company Overview

        16.5.2. Business Overview

        16.5.3. Financial Overview

        16.5.4. SWOT Analysis

        16.5.5. Strategic Overview

    16.6. Merck & Co., Inc.

        16.6.1. Company Overview

        16.6.2. Business Overview

        16.6.3. Financial Overview

        16.6.4. SWOT Analysis

        16.6.5. Strategic Overview

    16.7. MannKind Corporation

        16.7.1. Company Overview

        16.7.2. Business Overview

        16.7.3. Financial Overview

        16.7.4. SWOT Analysis

        16.7.5. Strategic Overview

    16.8. F. Hoffmann-La Roche Ltd.

        16.8.1. Company Overview

        16.8.2. Business Overview

        16.8.3. Financial Overview

        16.8.4. SWOT Analysis

        16.8.5. Strategic Overview

    16.9. Bristol-Myers Squibb Company

        16.9.1. Company Overview

        16.9.2. Business Overview

        16.9.3. Financial Overview

        16.9.4. SWOT Analysis

        16.9.5. Strategic Overview

    16.10. Mylan N.V.

        16.10.1. Company Overview

        16.10.2. Business Overview

        16.10.3. Financial Overview

        16.10.4. SWOT Analysis

        16.10.5. Strategic Overview

    16.11. Omron Corporation

        16.11.1. Company Overview

        16.11.2. Business Overview

        16.11.3. Financial Overview

        16.11.4. SWOT Analysis

        16.11.5. Strategic Overview

    16.12. 3M Healthcare

        16.12.1. Company Overview

        16.12.2. Business Overview

        16.12.3. Financial Overview

        16.12.4. SWOT Analysis

        16.12.5. Strategic Overview

    16.13. Sunovion Pharmaceuticals, Inc.

        16.13.1. Company Overview

        16.13.2. Business Overview

        16.13.3. Financial Overview

        16.13.4. SWOT Analysis

        16.13.5. Strategic Overview

    16.14. Koninklijke Philips N.V.

        16.14.1. Company Overview

        16.14.2. Business Overview

        16.14.3. Financial Overview

        16.14.4. SWOT Analysis

        16.14.5. Strategic Overview

    16.15. Gerresheimer AG

        16.15.1. Company Overview

        16.15.2. Business Overview

        16.15.3. Financial Overview

        16.15.4. SWOT Analysis

        16.15.5. Strategic Overview

    16.16. Bespak

        16.16.1. Company Overview

        16.16.2. Business Overview

        16.16.3. Financial Overview

        16.16.4. SWOT Analysis

        16.16.5. Strategic Overview

    16.17. AptarGroup, Inc.

        16.17.1. Company Overview

        16.17.2. Business Overview

        16.17.3. Financial Overview

        16.17.4. SWOT Analysis

        16.17.5. Strategic Overview

    16.18. SHL Group

        16.18.1. Company Overview

        16.18.2. Business Overview

        16.18.3. SWOT Analysis

        16.18.4. Strategic Overview

    16.19. Nypro Healthcare Inc. (Jabil Circuit Inc.)

        16.19.1. Company Overview

        16.19.2. Business Overview

        16.19.3. Financial Overview

        16.19.4. SWOT Analysis

        16.19.5. Strategic Overview

    16.20. Hovione

        16.20.1. Company Overview

        16.20.2. Business Overview

        16.20.3. Financial Overview

        16.20.4. SWOT Analysis

        16.20.5. Strategic Overview

    16.21. Chiesi Farmaceutici S.p.A.

        16.21.1. Company Overview

        16.21.2. Business Overview

        16.21.3. Financial Overview

        16.21.4. SWOT Analysis

        16.21.5. Strategic Overview

List of Tables

Table 01: Global Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (No. of Units) Forecast, by Product Type, 2017–2031

Table 02: Global Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Product Type, (Dry Powder Inhaler), 2017–2031

Table 03: Global Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Product Type, (Metered Dose Inhaler), 2017–2031

Table 04: Global Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Product Type, (Nebulizer), 2017–2031

Table 05: Global Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Application, 2017–2031

Table 06: Global Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Distribution Channel, 2017-2031

Table 07: Global Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (No. of Units) Forecast, by Region, 2017–2031

Table 08: North America Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Product Type, 2017–2031

Table 09: North America Pulmonary Drug Delivery Devices Volume (Million Units) Forecast, by Dry Powder Inhalers (Product) 2017–2031

Table 10: North America Pulmonary Drug Delivery Devices Volume (Million Units) Forecast, by Metered Dose Inhalers (Product) 2017–2031

Table 11: North America Pulmonary Drug Delivery Devices Volume (Million Units) Forecast, by Nebulizers (Product) 2017–2031

Table 12: North America Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Application, 2017–2031

Table 13: North America Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Distribution Channel 2017–2031

Table 14: North America Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Country, 2017–2031

Table 15: Europe Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Product Type, 2017–2031

Table 16: Europe Pulmonary Drug Delivery Devices Volume (Million Units) Forecast, by Product Type, (Dry Powder Inhaler) 2017–2031

Table 17: Europe Pulmonary Drug Delivery Devices Volume (Million Units) Forecast, by Product Type, (Metered Dose Inhaler) 2017–2031

Table 18: Europe Pulmonary Drug Delivery Devices and Volume (Million Units) Forecast, by Product Type, (Nebulizer) 2017–2031

Table 19: Europe Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Application, 2017–2031

Table 20: Europe Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Distribution Channel, 2017–2031

Table 21: Europe Pulmonary Drug Delivery Devices Market Size (US$ Mn) ) and Volume (Million Units) Forecast, by Country/Sub-region, 2017–2031

Table 22: Asia Pacific Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Product Type, 2017–2031

Table 23: Asia Pacific Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Product Type, (Dry Powder Inhaler) 2017–2031

Table 24: Asia Pacific Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Product Type, (Metered Dose Inhaler) 2017–2031

Table 25: Asia Pacific Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Product Type, (Nebulizer) 2017–2031

Table 26: Asia Pacific Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Application, 2017–2031

Table 27: Asia Pacific Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Distribution Channel, 2017–2031

Table 28: Asia Pacific Pulmonary Drug Delivery Devices Market Size (US$ Mn) ) and Volume (Million Units) Forecast, by Country/Sub-region, 2017–2031

Table 29: Latin America Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Product Type, 2017–2031

Table 30: Latin America Pulmonary Drug Delivery Devices Market Volume (Million Units) Forecast, by Product Type, (Dry Powder Inhaler) 2017–2031

Table 31: Latin America Pulmonary Drug Delivery Devices Market Volume (Million Units) Forecast, by Product Type, (Metered Dose Inhaler) 2017–2031

Table 32: Latin America Pulmonary Drug Delivery Devices Market Volume (Million Units) Forecast, by Product Type, (Nebulizer) 2017–2031

Table 33: Latin America Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Application, 2017–2031

Table 34: Latin America Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Distribution Channel, 2017–2031

Table 35: Latin America Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Country/Sub-region, 2017–2031

Table 36: Middle East & Africa Pulmonary Drug Delivery Devices Market Size Value (US$ Mn) and Volume (Million Units) Forecast, by Product Type, 2017–2031

Table 37: Middle East & Africa Pulmonary Drug Delivery Devices Market Volume (Million Units) Forecast, by Product Type, (Dry Powder Inhaler) 2017–2031

Table 38: Middle East & Africa Pulmonary Drug Delivery Devices Market Volume (Million Units) Forecast, by Product Type, (Metered Dose Inhaler) 2017–2031

Table 39: Middle East & Africa Pulmonary Drug Delivery Devices Market Volume (Million Units) Forecast, by Product Type, (Nebulizer) 2017–2031

Table 40: Middle East & Africa Pulmonary Drug Delivery Devices Market Size Value (US$ Mn) and Volume (Million Units) Forecast, by Application, 2017–2031

Table 41: Middle East & Africa Pulmonary Drug Delivery Devices Market Size Value (US$ Mn) and Volume (Million Units) Forecast, by Distribution Channel, 2017–2031

Table 42: Middle East & Africa Pulmonary Drug Delivery Devices Market Size (US$ Mn) ) and Volume (Million Units) Forecast, by Country/Sub-region, 2017–2031

List of Figures

Figure 01: Global Pulmonary Drug Delivery Devices Market Value Share Analysis, by Product Type, 2017–2031

Figure 02: Global Dry Powder Inhalers Market Revenue (US$ Mn) and Volume (Million Units) Growth Projections, 2017-2031

Figure 03: Global Dry Powder Inhalers Market Revenue (US$ Mn) and Volume Y-o-Y Growth Projections, 2017–2031

Figure 04: Global Metered Dose Inhalers Market Revenue (US$ Mn) and Volume (Million Units) Growth Projections, 2017–2031

Figure 05: Global Metered Dose Inhalers Market Revenue (US$ Mn) and Volume Y-o-Y Growth Projections, 2017–2031

Figure 06: Global Nebulizers Market Revenue (US$ Mn) and Volume (Million Units) Growth Projections, 2017–2031

Figure 07: Global Nebulizers Market Revenue (US$ Mn) and Volume Y-o-Y Growth Projections, 2017–2031

Figure 08: Global Single Dose Inhaler Market Volume and Y-o-Y Growth (%), 2017–2031

Figure 09: Global Multi Dose Inhaler Market Volume and Y-o-Y Growth (%), 2017-2031

Figure 10: Global Manually-actuated pressurized inhaler Market Volume and Y-o-Y Growth (%), 2017–2031

Figure 11: Global Breath-actuated pressurized inhaler Market Volume and Y-o-Y Growth (%), 2017-2031

Figure 12: Global Jet Nebulizers Market Volume and Y-o-Y Growth (%), 2017–2031

Figure 13: Global Ultrasonic Wave Nebulizers Market Volume and Y-o-Y Growth (%), 2017-2031

Figure 14: Global Vibrating Mesh Nebulizers Market Volume and Y-o-Y Growth (%), 2017-2031

Figure 15: Pulmonary Drug Delivery Devices Market Attractiveness Analysis, by Product Type

Figure 16: Global Pulmonary Drug Delivery Devices Market Value Share Analysis, by Application, 2017–2031

Figure 17: Global Asthma Market Revenue (US$ Mn) and Volume (Million Units) Growth Projections, 2017-2031

Figure 18: Asthma Market Revenue (US$ Mn) and Volume Y-o-Y Growth Projections, 2017–2031

Figure 19: Global COPD Market Revenue (US$ Mn) and Volume (Million Units) Growth Projections, 2017-2031

Figure 20: COPD Market Revenue (US$ Mn) and Volume Y-o-Y Growth Projections, 2017–2031

Figure 21: Global Cystic Fibrosis Market Revenue (US$ Mn) and Volume (Million Units) Growth Projections, 2017-2031

Figure 22: Cystic Fibrosis Market Revenue (US$ Mn) and Volume Y-o-Y Growth Projections, 2017–2031

Figure 23: Global Others Market Revenue (US$ Mn) and Volume (Million Units) Growth Projections, 2017-2031

Figure 24: Others Market Revenue (US$ Mn) and Volume Y-o-Y Growth Projections, 2017–2031

Figure 25: Pulmonary Drug Delivery Devices Market Attractiveness Analysis, by Application

Figure 26: Global Pulmonary Drug Delivery Devices Market Value Share Analysis, by Distribution Channel, 2017–2031

Figure 27: Global Retail Pharmacies Market Revenue (US$ Mn) and Volume (Million Units) Growth Projections, 2017-2031

Figure 28: Retail Pharmacies Market Revenue (US$ Mn) and Volume Y-o-Y Growth Projections, 2017–2031

Figure 29: Global Hospital Pharmacies Market Revenue (US$ Mn) and Volume (Million Units) Growth Projections, 2017-2031

Figure 31: Global E-commerce Market Revenue (US$ Mn) and Volume (Million Units) Growth Projections, 2017-2031

Figure 32: E-commerce Market Revenue (US$ Mn) and Volume Y-o-Y Growth Projections, 2017–2031

Figure 33: Pulmonary Drug Delivery Devices Market Attractiveness Analysis, by Distribution Channel

Figure 34: Global Pulmonary Drug Delivery Devices Market Value Share Analysis, by Region, 2017–2031

Figure 35: Pulmonary Drug Delivery Devices Market Attractiveness Analysis, by Region

Figure 36: North America Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, 2017-2031

Figure 37: North America Pulmonary Drug Delivery Devices Market Size and Volume Y-o-Y Growth Projections, 2017–2031

Figure 38: North America Pulmonary Drug Delivery Devices Market Attractiveness Analysis, by Country

Figure 39: North America Pulmonary Drug Delivery Devices Market Value Share Analysis, by Product, 2017–2031

Figure 40: North America Pulmonary Drug Delivery Devices Market Value Share Analysis, by Application, 2017–2031

Figure 41: North America Pulmonary Drug Delivery Devices Market Value Share Analysis, by Distribution Channel, 2017–2031

Figure 42: North America Pulmonary Drug Delivery Devices Market Value Share Analysis, by Country, 2017–2031

Figure 43: North America Pulmonary Drug Delivery Devices Market Attractiveness Analysis, by Product, 2022–2031

Figure 44: North America Pulmonary Drug Delivery Devices Market Attractiveness Analysis, by Application, 2022–2031

Figure 45: North America Pulmonary Drug Delivery Devices Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 46: Europe Pulmonary drug delivery devices Market Size (US$ Mn) and Volume (Million Units) Forecast, 2017-2031

Figure 47: Europe Pulmonary drug delivery devices Market Size and Volume Y-o-Y Growth Projections, 2017–2031

Figure 48: Europe Pulmonary drug delivery devices Market Attractiveness Analysis, by Country/Sub-region

Figure 49: Europe Market Value Share Analysis, by Product Type, 2017–2031

Figure 50: Europe Market Value Share Analysis, by Application, 2017–2031

Figure 51: Europe Market Value Share Analysis, by Distribution Channel, 2017–2031

Figure 52: Europe Pulmonary Drug Delivery Devices Market Value Share Analysis, by Country/Sub-region, 2017–2031

Figure 53: Europe Market Attractiveness Analysis, by Product Type, 2022–2031 

Figure 54: Europe Market Attractiveness Analysis, by Application, 2022–2031

Figure 55: Europe Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 56: Asia Pacific Pulmonary drug delivery devices Market Size (US$ Mn) and Volume (Million Units) Forecast, 2017-2031

Figure 57: Asia Pacific Pulmonary drug delivery devices Market Y-o-Y Analysis, by Country

Figure 58: Asia Pacific Market Attractiveness Analysis, by Country/Sub-region , 2022–2031

Figure 59: Asia Pacific Market Value Share Analysis, by Product Type, 2017–2031

Figure 60: Asia Pacific Market Value Share Analysis, by Application, 2017–2031

Figure 61: Asia Pacific Market Value Share Analysis, by Distribution Channel, 2017–2031

Figure 62: Asia Pacific Pulmonary Drug Delivery Devices Market Value Share Analysis, by Country/Sub-region, 2017–2031

Figure 63: Asia Pacific Market Attractiveness Analysis, by Product Type, 2022–2031

Figure 64: Asia Pacific Market Attractiveness Analysis, by Application, 2022–2031

Figure 65: Asia Pacific Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 66: Latin Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million units) Forecast, 2017-2031

Figure 67: Latin America Pulmonary Drug Delivery Devices Market Size and Volume Y-o-Y Growth Projections, 2017–2031

Figure 68: Latin America Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 69: Latin America Market Value Share Analysis, by Product Type, 2017–2031

Figure 70: Latin America Market Value Share Analysis, by Application, 2017–2031

Figure 71: Latin America Market Value Share Analysis, by Distribution Channel, 2017–2031

Figure 72: Latin America Market Value Share Analysis, by Country/Sub-region, 2017–2031

Figure 73: Latin America Market Attractiveness Analysis, by Product Type, 2022–2031

Figure 74: Latin America Market Attractiveness Analysis, by Application, 2022–2031

Figure 75: Latin America Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 76: MEA Market Size Value (US$ Mn) and Volume (Million Units) Forecast, 2017-2031

Figure 77: MEA Pulmonary Drug Delivery Devices Market Size and Volume Y-o-Y Growth Projections, 2017–2031

Figure 78: Middle East & Africa Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 79: Middle East & Africa Market Value Share Analysis, by Product Type, 2017–2031

Figure 80: Middle East & Africa Market Value Share Analysis, by Application, 2017–2031

Figure 81: Middle East & Africa Market Value Share Analysis, by Distribution Channel, 2017–2031

Figure 82: Middle East & Africa Pulmonary Drug Delivery Devices Market Value Share Analysis, by Country/Sub-region, 2017–2031

Figure 83: Middle East & Africa Market Attractiveness Analysis, by Product Type, 2022–2031

Figure 84: Middle East & Africa Market Attractiveness Analysis, by Application, 2022–2031

Figure 85: Middle East & Africa Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 86: Global Pulmonary Drug Delivery Devices Market Share Analysis, by Company, 2021

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

521

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved